Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Overexpression of Holocarboxylase Synthetase Predicts Lymph Node Metastasis and Unfavorable Prognosis in Breast Cancer
Authors: Witchuda Sukjoi
Siraprapa Siritutsoontorn
Pakkanan Chansongkrow
Suppakit Waiwitlikhit
Steven W. Polyak
Malee Warnnissorn
Varodom Charoensawan
Chanitra Thuwajit
Sarawut Jitrapakdee
University of South Australia
Mahidol University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Brighton College
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Aug-2020
Citation: Anticancer research. Vol.40, No.8 (2020), 4557-4565
Abstract: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. BACKGROUND/AIM: Holocarboxylase synthetase (HLCS) catalyzes the specific attachment of biotin onto biotin-dependent carboxylases (BDCs) which play important roles in intermediary metabolism. Previous studies show that BDCs are overexpressed in many cancer types. However, expression of HLCS in cancerous tissues has not been reported. MATERIALS AND METHODS: Immunohistochemistry was used to investigate HLCS expression in breast tissue obtained from 65 Thai patients, and the correlation between its expression and key clinical-pathological parameters was assessed. The role of HLCS in supporting invasion was investigated in HLCS-knockdown MCF-7 cells. RESULTS: Overexpression of HLCS was significantly associated with metastasis of breast cancer cells to other lymph nodes but not the sentinel and axillary lymph nodes - a finding supported in cellular invasion assays using HLCS knockdown cells. Furthermore, overexpression of HLCS reduced survival time of patients with breast cancer. CONCLUSION: HLCS appears to be a prognostic marker for patients with breast cancer.
ISSN: 17917530
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.